Biologic Cost per Effectively Treated Rheumatoid Arthritis Patient in a Large Managed Care Population: A Retrospective Cohort Study
**Background:** Until recently, the lack of clinical outcomes information for rheumatoid arthritis (RA) in administrative claims databases limited their use in comparative effectiveness research. A validated claims-based algorithm has been developed to estimate the effectiveness of biologics for RA,...
Saved in:
Main Authors: | Tao Gu, Neel Shah, Gaurav Deshpande, Derek H. Tang, Debra F. Eisenberg, David J. Harrison |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2015-09-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/9830 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analysis of periodontal status in Polish patients with rheumatoid arthritis treated with biological therapies
by: Joanna Samborska-Mazur, et al.
Published: (2024-11-01) -
The research progress of biologics in elderly-onset rheumatoid arthritis (EORA)
by: Yujie Li, et al.
Published: (2025-01-01) -
Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis
by: Cynthia Said, et al.
Published: (2013-01-01) -
Influence of Biological Therapeutics, Cytokines, and Disease Activity on Depression in Rheumatoid Arthritis
by: Margarida Figueiredo-Braga, et al.
Published: (2018-01-01) -
Adiponectin and rheumatoid arthritis
by: Beuy Joob, et al.
Published: (2019-01-01)